2020
Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
Numan Y, Rahman Z, Grenet J, Boisclair S, Bewersdorf J, Barth D, Zeidan A, Yilmaz M, Dinner S, Deutsch Y, Frankfurt O, Litzow M, Al-Kali A, Foran J, Sproat L, Jovanovic B, Daver N, Perl A, Altman J. Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. Blood 2020, 136: 5-7. DOI: 10.1182/blood-2020-137251.Peer-Reviewed Original ResearchStem cell transplantMedian survivalFLT3 mutationsBristol-Myers SquibbDaiichi SankyoBoehringer IngelheimCRC ratesLymphoma SocietyCombination therapyPolymerase chain reactionFLT3-ITDSingle agentDrug resistanceAdvisory CommitteeBone marrow flow cytometryComposite complete remissionFLT3-D835 mutationsHigher CRCS ratesNon-transplanted patientsPoor median survivalKaplan-Meier curvesMulti-institutional analysisLog-rank testBayer HealthCare PharmaceuticalsMAPK pathway
2018
Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study. Blood 2018, 132: 4865. DOI: 10.1182/blood-2018-99-119118.Peer-Reviewed Original ResearchUse of statinsIncidence of thrombosisStatin usersLog-rank testRisk of thrombosisOverall survivalEssential thrombocythemiaET diagnosisPercentage of daysHydrophilic statinsOlder adultsET patientsMultivariate Cox proportional hazards modelLarge population-based cohort studyContinuous Medicare Parts APopulation-based cohort studyCox proportional hazards modelEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesPopulation-based cohortEnd of studyProportional hazards modelPart DUse of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580. DOI: 10.1182/blood-2018-99-119272.Peer-Reviewed Original ResearchStatin usersImpact of statinsLog-rank testRisk of thrombosisOverall survivalPercentage of daysPV patientsMyeloproliferative neoplasmsPV diagnosisMultivariate Cox proportional hazards modelContinuous Medicare Parts ACox proportional hazards modelCardiovascular risk factorsEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesType of statinPopulation-based cohortNumber of phlebotomiesEnd of studyProportional hazards modelPart DMedicare Part AHealth maintenance organization
2013
The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)
Zeidan A, Al Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza). Blood 2013, 122: 2771. DOI: 10.1182/blood.v122.21.2771.2771.Peer-Reviewed Original ResearchMD Anderson Prognostic Scoring SystemMedian overall survivalHigh-risk groupMoffitt Cancer CenterAZA therapyHR-MDSOverall survivalPrognostic scoring systemMyelodysplastic syndromeIntermediate riskRisk groupsLower riskScoring systemPrognostic groupsInt-2Therapy-related myelodysplastic syndromeHigh-risk myelodysplastic syndromeCycles of therapyHR-MDS patientsKaplan-Meier curvesLog-rank testOff-label useAZA initiationRevised IPSSR-IPSS